MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM

被引:28
作者
Casaletto, Jessica B. [1 ]
Geddie, Melissa L. [1 ]
Abu-Yousif, Adnan O. [1 ]
Masson, Kristina [1 ]
Fulgham, Aaron [1 ]
Boudot, Antoine [1 ]
Maiwald, Tim [1 ]
Kearns, Jeffrey D. [1 ]
Kohli, Neeraj [1 ]
Su, Stephen [1 ]
Razlog, Maja [1 ]
Raue, Andreas [1 ]
Kalra, Ashish [1 ]
Hakansson, Maria [2 ]
Logan, Derek T. [2 ]
Welin, Martin [2 ]
Chattopadhyay, Shrikanta [1 ]
Harms, Brian D. [1 ]
Nielsen, Ulrik B. [1 ]
Schoeberl, Birgit [1 ]
Lugovskoy, Alexey A. [1 ]
MacBeath, Gavin [1 ]
机构
[1] Merrimack Pharmaceut Inc, Discovery Div, Cambridge, MA 02139 USA
[2] SAR Biostruct AB, SE-22381 Lund, Sweden
关键词
bispecific antibody; Met; HGF; EpCAM; cancer; HEPATOCYTE GROWTH-FACTOR; TIVANTINIB ARQ 197; RANDOMIZED PHASE-II; C-MET; ONCOGENE ADDICTION; CRYSTAL-STRUCTURE; INVASIVE GROWTH; PLUS ERLOTINIB; LUNG-CANCER; AMPLIFICATION;
D O I
10.1073/pnas.1819085116
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Activation of the Met receptor tyrosine kinase, either by its ligand, hepatocyte growth factor (HGF), or via ligand-independent mechanisms, such as MET amplification or receptor overexpression, has been implicated in driving tumor proliferation, metastasis, and resistance to therapy. Clinical development of Met-targeted antibodies has been challenging, however, as bivalent antibodies exhibit agonistic properties, whereas monovalent antibodies lack potency and the capacity to down-regulate Met. Through computational modeling, we found that the potency of a monovalent antibody targeting Met could be dramatically improved by introducing a second binding site that recognizes an unrelated, highly expressed antigen on the tumor cell surface. Guided by this prediction, we engineered MM-131, a bispecific antibody that is monovalent for both Met and epithelial cell adhesion molecule (EpCAM). MM-131 is a purely antagonistic antibody that blocks ligand-dependent and ligand-independent Met signaling by inhibiting HGF binding to Met and inducing receptor down-regulation. Together, these mechanisms lead to inhibition of proliferation in Met-driven cancer cells, inhibition of HGF-mediated cancer cell migration, and inhibition of tumor growth in HGF-dependent and -independent mouse xenograft models. Consistent with its design, MM-131 is more potent in EpCAM-high cells than in EpCAM-low cells, and its potency decreases when EpCAM levels are reduced by RNAi. Evaluation of Met, EpCAM, and HGF levels in human tumor samples reveals that EpCAM is expressed at high levels in a wide range of Met-positive tumor types, suggesting a broad opportunity for clinical development of MM-131.
引用
收藏
页码:7533 / 7542
页数:10
相关论文
共 74 条
[11]   A Heterodimeric Fc-Based Bispecific Antibody Simultaneously Targeting VEGFR-2 and Met Exhibits Potent Antitumor Activity [J].
Choi, Hye-Ji ;
Kim, Ye-Jin ;
Lee, Sangho ;
Kim, Yong-Sung .
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (12) :2748-2759
[12]   Drug development of MET inhibitors: targeting oncogene addiction and expedience [J].
Comoglio, Paolo M. ;
Giordano, Silvia ;
Trusolino, Livio .
NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (06) :504-516
[13]   False-negative rate for HER2 testing in 738 gastric and gastroesophageal junction cancers (GEC) from two global randomized clinical trials [J].
Cunningham, David ;
Shah, Manish A. ;
Smith, Dustin ;
Zoudilova, Maria ;
Hack, Stephen Paul ;
Kang, Alice ;
Phan, See-Chun ;
Jubb, Adrian M. ;
Ruschoff, Josef .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[14]   Crystal structure of deglycosylated human IgG4-Fc [J].
Davies, Anna M. ;
Jefferis, Roy ;
Sutton, Brian J. .
MOLECULAR IMMUNOLOGY, 2014, 62 (01) :46-53
[15]   Structural Determinants of Unique Properties of Human IgG4-Fc [J].
Davies, Anna M. ;
Rispens, Theo ;
Heer, Pleuni Ooijevaar-de ;
Gould, Hannah J. ;
Jefferis, Roy ;
Aalberse, Rob C. ;
Sutton, Brian J. .
JOURNAL OF MOLECULAR BIOLOGY, 2014, 426 (03) :630-644
[16]  
Davies J, 2015, US Patent, Patent No. [US 9,201,074 B2, 9201074]
[17]   Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer [J].
De Bacco, Francesca ;
Luraghi, Paolo ;
Medico, Enzo ;
Reato, Gigliola ;
Girolami, Flavia ;
Perera, Timothy ;
Gabriele, Pietro ;
Comoglio, Paolo M. ;
Boccaccio, Carla .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (08) :645-661
[18]   Antiparallel Conformation of Knob and Hole Aglycosylated Half-Antibody Homodimers Is Mediated by a CH2-CH3 Hydrophobic Interaction [J].
Elliott, J. Michael ;
Ultsch, Mark ;
Lee, Joshua ;
Tong, Raymond ;
Takeda, Kentaro ;
Spiess, Christoph ;
Eigenbrot, Charles ;
Scheer, Justin M. .
JOURNAL OF MOLECULAR BIOLOGY, 2014, 426 (09) :1947-1957
[19]   MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].
Engelman, Jeffrey A. ;
Zejnullahu, Kreshnik ;
Mitsudomi, Tetsuya ;
Song, Youngchul ;
Hyland, Courtney ;
Park, Joon Oh ;
Lindeman, Neal ;
Gale, Christopher-Michael ;
Zhao, Xiaojun ;
Christensen, James ;
Kosaka, Takayuki ;
Holmes, Alison J. ;
Rogers, Andrew M. ;
Cappuzzo, Federico ;
Mok, Tony ;
Lee, Charles ;
Johnson, Bruce E. ;
Cantley, Lewis C. ;
Janne, Pasi A. .
SCIENCE, 2007, 316 (5827) :1039-1043
[20]  
FERRACINI R, 1995, ONCOGENE, V10, P739